TMZ, an alkylating agent, has clear anti-tumor activity as a monotherapy in treating gliomas, particularly effective in gliomas with low expression of MGMT (methylguanine-DNA methyltransferase) [34]. This evidence concerns the gene MGMT and central nervous system cancer.